• OPEN AN ACCOUNT
Indian Indices
Sensex
78,499.17 -455.59
( -0.58%)
Global Indices
Nasdaq
54,056.75 150.65
(0.28%)
Dow Jones
7,778.11 47.15
(0.61%)
Hang Seng
65,597.55 -85.71
(-0.13%)
Nikkei 225
10,909.12 41.23
(0.38%)
Forex
USD-INR
95.20 0.13
(0.14%)
EUR-INR
109.83 0.08
(0.08%)
GBP-INR
128.13 0.14
(0.11%)
JPY-INR
0.60 0.00
(-0.12%)

EQUITY - MARKET SCREENER

Grovy India Ltd
Industry :  Construction
BSE Code
ISIN Demat
Book Value()
539522
INE343C01012
21.7435578
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
26.42
98.03
EPS(TTM)
Face Value()
Div & Yield %
2.12
10
0.14
 

Natco Pharma tanks after Q4 profit declines 34% YoY to Rs 268 cr
May 29,2026
Revenue from operations fell 39.46% YoY to Rs 739.1 crore in the quarter ended 31 March 2026.

Profit before tax (PBT) declined sharply by 71.51% to Rs 144.1 crore in Q4 FY26 from Rs 505.9 crore recorded in Q4 FY25.

On the segmental front, revenue from the pharmaceuticals business stood at Rs 716.5 crore, down 40.58% year-on-year. Meanwhile, revenue from the agro chemicals segment increased 50.66% YoY to Rs 716.5 crore in Q4 FY26.

For the full financial year FY26, Natco Pharma reported a 24.76% decline in consolidated net profit to Rs 1,418.5 crore. Revenue from operations decreased 7.92% year-on-year to Rs 4,078.3 crore in FY26.

NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.